Literature DB >> 31009724

Retrograde Type A Intramural Hematoma Treated Endovascularly in Two Cases.

Filip W N Haenen1, Emma Van Der Weijde2, Jan-Albert Vos3, Robin H Heijmen4.   

Abstract

Type A aortic dissection is a highly lethal condition, which warrants swift open surgical intervention to prevent death by rupture or malperfusion. The aim is to resect the proximal intimal tear and realign the dissected wall layers. We describe two patients who recently presented in our center with a retrograde type A intramural hematoma and a clear intimal tear distal to the left subclavian artery, that were treated in emergency by endovascular means instead of open surgery, with satisfactory short-term and one-year follow-up results. In conclusion, in selected cases, less invasive thoracic endovascular aortic repair can treat retrograde type A intramural hematoma originating from an intimal tear distal to the left subclavian artery, with good one-year results.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31009724     DOI: 10.1016/j.avsg.2018.12.107

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  3 in total

Review 1.  Management of retrograde type A IMH with acute arch tear/type B dissection.

Authors:  Foeke Nauta; Hector de Beaufort; Firas F Mussa; Carlo De Vincentiis; Atsushi Omura; Hitoshi Matsuda; Santi Trimarchi
Journal:  Ann Cardiothorac Surg       Date:  2019-09

2.  Endovascular repair for retrograde type A intramural hematoma with focal intimal disruption in descending aorta.

Authors:  Jiehua Li; Xiaolong Zhang; Yuan Peng; Lunchang Wang; Tun Wang; Xin Li; Hao He; Quanming Li; Chang Shu
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

3.  Note the descending aorta: predictors of postoperative major adverse aortic event in pure acute type A intramural hematoma.

Authors:  Myeong Su Kim; Tae-Hoon Kim; Ha Lee; Suk-Won Song; Woon Heo; Seo-A Sim; Kyung-Jong Yoo
Journal:  J Thorac Dis       Date:  2021-08       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.